Prevention of sudden coronary death
Czechoslovak Medicine
|January 1, 1991
Summary
Lidocaine antiarrhythmics increase fibrillation risk during myocardial ischemia. Beta blockers with intrinsic sympathetic activity and analgosedation (fentanyl/midazolam) offer cardiac electrostability and prevent sudden death.
Area of Science:
- Cardiology
- Pharmacology
- Experimental Medicine
Background:
- Myocardial ischemia can lead to life-threatening ventricular fibrillation.
- The electrophysiological effects of various drugs during acute ischemia require further investigation for optimal patient management.
Purpose of the Study:
- To evaluate the pro-fibrillation and electrostabilizing effects of specific antiarrhythmics, beta-blockers, and analgosedation in a canine model of myocardial ischemia.
- To determine the potential of these agents in preventing sudden cardiac death associated with acute myocardial ischemia.
Main Methods:
- Experimental study in dogs under pentobarbital anesthesia.
- Induction of myocardial ischemia via artery ligation.
- Administration and assessment of lidocaine-type antiarrhythmics, beta-blockers (celiprolol, metipranolol), and analgosedation (fentanyl/midazolam).
Main Results:
- Lidocaine-type antiarrhythmics demonstrated a pro-fibrillation effect, inversely proportional to ischemic focus development.
- Third-generation beta-blockers (celiprolol) and first-generation beta-blockers (metipranolol) showed similar ventricular electrostabilizing effects.
- Analgosedation (fentanyl/midazolam) provided analgesia and cardiac electrostability, allowing for reduced analgesic dosage and less impact on heart rate and blood pressure.
Conclusions:
- Analgosedation and beta-blockers with intrinsic sympathetic action are recommended for preventing sudden coronary death during acute myocardial ischemia.
- Lidocaine antiarrhythmics may reduce ventricular electrostability, particularly at critical blood levels during ischemic focus development.
- Analgosedation can be safely reversed without compromising the electrostabilizing effect on ischemic ventricles.
More Related Videos
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...